ATC Group: L01BB03 Tioguanine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01BB03 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01B Antimetabolites
4 L01BB Purine analogues
5 L01BB03 Tioguanine

Active ingredients in L01BB03

Active Ingredient Description
Tioguanine

Tioguanine is a sulphydryl analogue of guanine and behaves as a purine antimetabolite. It is activated to its nucleotide, thioguanylic acid. Tioguanine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions. Tioguanine is also incorporated into nucleic acids and DNA (deoxyribonucleic acid) incorporation is claimed to contribute to the agent’s cytotoxicity.

Related product monographs

Title Information Source Document Type  
LANVIS Health Products Regulatory Authority (IE) MPI, EU: SmPC
TIOGUANINE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Brazil (BR)

Canada (CA)

Estonia (EE)

France (FR)

Hong Kong (HK)

Ireland (IE)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

South Africa (ZA)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.